Title: Using the combined 70- and 80-gene signatures on core needle biopsy to guide neoadjuvant chemotherapy recommendations for invasive breast cancer in a Black population: Can we identify those who benefit most at time of diagnosis? Using the combined 70- and 80-gene signatures on core needle biopsy to guide neoadjuvant chemotherapy recommendations for invasive breast cancer in a Black population: Can we identify those who benefit most at time of diagnosis?
Publication: SSO 2024
Authors: Solis-Pomales MD, et al.
Objective: To examine how MammaPrint (MP) and BluePrint (BP) results affected treatment decisions (Neoadjuvant chemotherapy (NAC) vs surgery first) and tumor response in a Black patient population.
Conclusion:
- Black patients with genomically high risk tumors, defined by MP and BP on CNB, were more frequently recommended for NAC and subsequently downstaged and/or achieved complete response.
- MP/BP can be an important tool in the treatment planning of Black patients.
